Table 2.
Clinical and Laboratory Characteristics at Diagnosis of Patients With Essential Thrombocythemia According to Type of Mutation.
| Parameters | Total | JAK2V617F(+) I | CALR(+) II | MPL(+) III | JAK2V617F(−) CALR(−) MPL(−) IV |
|---|---|---|---|---|---|
| Patients | 60 | 37 | 7 | 1 | 15 |
| % | 100.0 | 61.7 | 11.7 | 1.7 | 25.0 |
| F/M | 38/22 | 24/13 | 5/2 | F | 8/7 |
| Age | 61 | 62 | 62 | 68 | 56.5 |
| Range | 21-86 | 21-86 | 27-80 | 24-78 | |
| History of thrombosis | 18 | 12 | 1 | No | 5 |
| WBC, G/L | 10.1 | 10.6 | 9.0 | 8.3 | 9.4 |
| Range | 4.1-16.3 | 4.1-16.3 | 7.1-11.1 | 4.8-13.1 | |
| RBC, T/L | 4.9 | 5.3a | 4.7 | 3.6 | 4.8a |
| Range | 2.7-7.5 | 2.7-7.5 | 4.1-4.9 | 3.9-6.1 | |
| Hemoglobin, g/dL | 14.5 | 14.7a,b | 14.1b | 9.6 | 14.0a |
| Range | 8.4-18.8 | 8.4-18.8 | 11.7-15.0 | 9.8-15.9 | |
| Platelets, G/L | 873.0 | 893 | 793 | 1139 | 811 |
| Range | 416.0-2165 | 416-2165 | 638-1500 | 461-1281 | |
| VEGF-A, pg/mL | 104.65 | 98.7 | 139.7 | 196.8 | 106.2 |
| Quartiles | 52.24; 208.63 | 42.6; 256.3 | 91.4; 333.4 | 62.1; 146.0 | |
| sVEGFR-1, pg/mL | 100.7 | 105.0 | 101.3 | 87.2 | 88.5 |
| Quartiles | 74.56; 130.90 | 74.6; 121.4 | 77.8; 126.6 | 61.5; 163.5 | |
| sVEGFR-2, pg/mL | 8241.0 | 8053.2 | 8915.1 | 7399.5 | 8445.70 |
| ±SD | ±2249.1 | ±1981.4 | ±1493.6 | ±3138.5 | |
| PDGF-BB, pg/mL | 321.6 | 308.5c | 875.9c | 841.3 | 249.3 |
| Quartiles | 148.7; 841.3 | 133.7; 622.3 | 630.9; 1137.4 | 49.8; 1142.8 | |
| SDF-1α, pg/mL | 2122.1 | 2230.4c | 1692.6c | 1889.9 | 1983.5 |
| Quartiles | 1766.2; 2437.7 | 1908.6; 2515.5 | 1583.1; 2122.1 | 1656.0; 2437.7 |
Abbreviations: CALR, calreticulin gene; JAK2, Janus kinase 2; SD, standard deviation; WBC, white blood cell.
aI vs IV P < .05.
bI vs II P < .05.
cI vs II P < .05.